Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alismatis rhizoma
- Development stage
- Preclinical
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Alismatis Rhizoma is a traditional Chinese medicine (TCM) derived from the dried rhizomes of *Alisma orientale* (Sam.) Juzep. or *Alisma plantago-aquatica* Linn. It is widely utilized for its diuretic, lipid-lowering, and anti-inflammatory properties. The therapeutic efficacy of Alismatis Rhizoma is attributed to its diverse chemical constituents, primarily triterpenoids (such as alisol A, alisol B 23-acetate, and alisol C 23-acetate) and polysaccharides (arabinogalactans). Research indicates that these components exert protective effects against metabolic dysfunction-associated steatohepatitis (MASH), hyperlipidemia, and obesity by modulating targets such as SIRT1, pancreatic lipase, and bile acid-CoA: amino acid N-acyltransferase (BAAT). Additionally, Alismatis Rhizoma has shown potential in treating acute liver injury, diabetic nephropathy, and hypertension through multi-target regulatory paradigms involving the activation of JNK/p38 MAPK signaling and the modulation of gut microbiota.
- Other names
- ZexieAlisma orientaleAlisma plantago-aquaticaAlismatis Rhizoma polysaccharideARPAlisma starch
02
Targets
EGFR (Epidermal growth factor receptor)FXR (Farnesoid x-activated receptor)MAPK3 (Mitogen-activated protein kinase 1)PNLIP (Pancreatic triacylglycerol lipase)SRC (Proto-oncogene tyrosine-protein kinase Src)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)JNK (Mitogen-activated protein kinase kinase kinase family)RK (Ribokinase)BAAT (Bile acid-CoA:amino acid N-acyltransferase)GehA (Triacylglycerol lipase GehA)MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on alismatis rhizoma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alismatis rhizoma.